Lipid metabolism disorders: diagnosis and treatment

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Full Text

Restricted Access

About the authors

Olga A. Mubarakshina

Voronezh State Medical University n.a. N.N. Burdenko

Author for correspondence.
Email: mubarakshina@mail.ru
ORCID iD: 0000-0001-6799-6322

Cand. Sci. (Med.)

Russian Federation, Voronezh

Olga A. Zhdanova

Voronezh State Medical University n.a. N.N. Burdenko

Email: olga.vr9@yandex.ru
ORCID iD: 0000-0002-3917-0395
SPIN-code: 1235-9770

Dr. Sci. (Med.), Associate Professor, Professor of the Department of Clinical Pharmacology

Russian Federation, Voronezh

References

  1. Нарушения липидного обмена. Клинические рекомендации. 2025. URL: https://cr.minzdrav.gov.ru/view-cr/752_1 [Lipid metabolism disorders. Clinical guidelines. 2025. URL: https://cr.minzdrav.gov.ru/view-cr/752_1 (In Russ.)].
  2. Болезни сердца по Браунвальду: руководство по сердечно-сосудистой медицине. под ред. П. Либби и др.; пер. с англ. под общ. ред. Р.Г. Оганова. В 4-х т. Том 1. М.: Логосфера, 2012. 596 с.: ил. [Braunwald’s heart disease: a textbook of cardiovascular medicine. Ed. by P. Libby et al.; translation from English. General editor R.G. Oganov. In 4 volumes. Volume 1. Moscow: Logosfera, 2012. 596 p.: ill. (In Russ.)].
  3. Liu J., et al. Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids in Health and Disease. 2013;12(1):1–11.
  4. Amarenco P., Labreuche J.. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology. 2009;8(5):453–463.
  5. Ershova A., Balakhonova T., Meshkov A., et al. Carotid and femoral artery plaques as predictors of cardiovascular and all-cause mortality in the middle-aged general population. Atherosclerosis Supplements. 2022;355:e43–e44. doi: 10.1016/j.atherosclerosis.2022.06.212.
  6. Ежов М.В., Бажан С.С., Ершова А.И. и др. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019;15(1):58–98. [Ezhov M.V., Bazhan S.S., Ershova A.I., et al. Clinical guidelines for familial hypercholesterolemia. Ateroscleroz. 2019;15(1):58–98. (In Russ.)].
  7. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–2454.
  8. Holewijn S., et al. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Int Med. 2010;268(6):567–577.
  9. Blonde L., Umpierrez G.E., Reddy S.S., et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923–1049. doi: 10.1016/j.eprac.2022.08.002.
  10. Pletcher M.J., et al. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Int Med. 2004;164(12):1285–1292.
  11. Балахонова Т.В., Ершова А.И., Ежов М.В. и др. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):3333. doi: 10.15829/1728-8800-2022-3333.
  12. Eckel R.H., Jakicic J.M., Ard J.D., et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. Circulation. 2013;129(25 suppl 2):S76–S99. doi: 10.1161/01.cir.0000437740.48606.d1
  13. Estruch R., Ros E., Salas-Salvado J., et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi: 10.1056/NEJMoa1800389.
  14. Oscarsson J., Önnerhag K., Riserus U., et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. J Clin Lipidol. 2018 Nov-Dec;12(6):1390–1403.e4. doi: 10.1016/j.jacl.2018.08.003.
  15. Lu Z., Kou W., Du B., et al. Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction. Am J Cardiol. 2008;101(12):1689–93. doi: 10.1016/j.amjcard.2008.02.056.
  16. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database System Rev. 2013. doi: 10.1002/14651858.cd004816.pub5.
  17. Vallejo-Vaz A.J., et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. 2018;138(8):770–781.
  18. Bohula E.A., Wiviott S.D., Giugliano R.P., et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017;136:2440–2450. doi: 10.1161/CIRCULATIONAHA.117.029095.
  19. Schreml J., Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. Current medicinal chemistry. 2018;25(13):1538–1548.
  20. Klebs S., Lecocq J., Mann С., et al. Characterization of Inclisiran Use in Real World: Prescription Data from Germany. J Clin Lipidol. 2022;16(3):Suppl e73. doi: 10.1016/j.jacl.2022.05.060.
  21. Rohit D., Shankar J. Comparative Study of Atorvastatin and Rosuvastatin in Combination with Fenofibrate in mixed Hyperlipidemia. Int J Pharmacol Clin Sci. 2016;5(1):25–31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. DIAGNOSTICS OF DYSLIPDEMIA

Download (730KB)
Indexing metadata
3. TREATMENT OF LIPID METABOLISM DISORDERS

Download (696KB)
Indexing metadata

Copyright (c) 2025 Bionika Media